Cartesian Therapeutics

top of page

Cartesian Therapeutics is working on CAR-T for autoimmune conditions, but with the unique angle that it is using a mRNA approach rather than DNA

Chairman & CEO Carsten Brunn describes the potential advantages of this, which includes that no lymphodepletion is needed. The company is currently in a pivotal study for myasthenia gravis.

Company News

2 hours ago

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

Learn more

bottom of page

Cartesian Therapeutics is working on CAR-T for autoimmune conditions, but with the unique angle that it is using a mRNA approach rather than DNA

Follow BiotechTV

Sponsors

Sponsor Spotlight